Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanism and Clinical Evidence

BTK inhibitors represent an emerging oral therapeutic class for MS that can target both adaptive and innate immune pathways, with some agents crossing the blood-brain barrier to address progressive MS pathology resistant to current treatments. Phase 2 and 3 trial data show promise, particularly for agents like tolebrutinib in secondary progressive MS disability progression.